Because of "field cancerization", mucosa of the upper digestive tract may be exposed to common carcinogens and the epithelium are at risk of malignant transformation either synchronously or metachronously of the index primary malignancy[@b1]. The development of second primary tumors (SPTs), especially in the head and neck, lung and esophagus regions, is not uncommon in head and neck squamous cell carcinoma (HNSCC) patients and the occurrence of SPTs is one of the leading causes of mortality[@b2][@b3]. The incidence of synchronous SPTs in HNSCC patients varies from 7% to 36%[@b4][@b5][@b6][@b7][@b8][@b9]. Additionally, the cumulative incidence of SPTs may be as high as 23.1% at 10 years and 36% at 20 years after the diagnosis of primary tumors[@b3][@b9]. Because the diversity of second cancers, it is still a challenge to manage the second cancers of different anatomic site in HNSCC patients.

The 5-year overall survival rate of esophageal cancer is less than 10\~20% worldwide[@b10]. The most important reason for the poor prognosis is late diagnosis at advanced symptomatic stage. Among different sites of SPT in HNSCC patients, esophageal squamous cell neoplasia (ESCN) is the most common one involving the digestive tract[@b2][@b3][@b4][@b5][@b7][@b8][@b11][@b12]. Several studies have also demonstrated a worse prognosis for synchronous or metachronous ESCN in HNSCC patients[@b2][@b3]. Given that superficial ESCNs have lower chance for lymph node (LN) metastasis, whereas epithelial and lamina propria cancers have no risk for LN metastasis, and \<10% of muscularis mucosa cancers and about 20% of superficial submucosa carcinomas have LN metastasis, the prognosis of patients with superficial ESCN is excellent, with 5-year survival rates over 80%[@b13][@b14]. Therefore, through endoscopic screening of esophagus in HNSCC patients, especially using image-enhanced endoscopy (IEE) technique, a substantial proportion of 3.2\~28% ESCN could be identified before obstructive symptoms develop, and it was believed that with screening early ESCN before treatment of index primary tumor is associated with better outcome for HNSCC patients[@b15][@b16].

At present, no standard treatments or guideline recommendations available to define whether index primary tumors or SPTs to be treated first. In addition, most of the previous reported screening ESCN in HNSCC patients are at precancerous or early cancerous stages, and about 15.5%\~23.3% treatment strategy of HNSCC patients may be modified after detection of esophageal SPTs[@b4][@b7][@b8][@b15][@b16]. Although several retrospective studies reported routine IEE screening in newly diagnosed HNSCC patients could improve survival comparing to historic cohort[@b16][@b17], without a prospective study, the long-term survival of these IEE identified HNSCC with ESCNs is still unclear. The aim of this study was to evaluate the prognosis of HNSCC patients with synchronous ESCN after IEE screening and to investigate the impacts of endoscopic screening on the treatment strategy and survival of index primary tumors.

Materials and Methods
=====================

Study Design
------------

We prospectively recruited adults older than 20-year-old who had newly diagnosed head and neck cancers that were confirmed by two otolaryngology head and neck surgeons (L.-J. L., W.-C. L.) from March 2010 to April 2013 at the Far Eastern Memorial Hospital in New Taipei City, Taiwan. We excluded patients with salivary gland tumors, those who needed emergent surgery for compromised airways or tumor bleeding, trismus, allergic history to iodine and pregnant or those refused esophagogastroduodenoscopy (EGD) screening of esophagus. All enrolled patients were referred to gastroenterologists for EGD screening using IEE before treatment of index primary tumors. All the enrolled patients provided written informed consent before endoscopic examination. This study was approved by the Research Ethics Review Committee of Far Eastern Memorial Hospital (FEMH IRB-101022-E) and the methods were carried out in accordance with the relevant guidelines.

Endoscopic screening of esophagus
---------------------------------

All of the patients received endoscopic examinations using narrow-band imaging (NBI) with magnifying endoscopy (ME) which has powerful 80 times optical magnification (Evis Lucera CLV-260NBI, GIF-H260Z endoscopy, Olympus Medical Systems Corp, Tokyo, Japan), and chromoendoscopy with 2% Lugol's solution (Sigma-Aldrich, St. Louis, Missouri, USA). NBI-ME and Lugol chromoendoscopy have been shown to identify second primary neoplasm in esophageal and head and neck cancer patients with pooled sensitivity and specificity of 87% and 95%, and 88% and 63%, respectively[@b18]. All endoscopic examinations and endoscopic submucosal dissection (ESD) of ESCN were performed by one experienced endoscopist (C.-S. C.) who had performed more than 250 EGDs equipped with NBI system and 4 ESDs monthly for 5 years. After an overnight fast, the patients swallowed a simethicone solution followed by local pharyngeal anesthesia with 10% xylocaine spraying. First, the esophagus was examined by conventional white-light imaging (WLI) endoscopy from the esophageal inlet to the esophagogastric junction, and then repeatedly evaluated backward under NBI-ME for esophagus. Secondly, after NBI examination, we switched back to WLI and sprayed 10 to 20 mL of 2% Lugol's solution evenly over the mucosa from esophagogastric junction to upper esophagus. The definition of suspected ESCNs were defined as a hyperemic change, uneven or nodularity of mucosa under WLI system ([Fig. 1C](#f1){ref-type="fig"}), or brownish discoloration of mucosa with abnormal intraepithelial capillary papillary loops (IPCLs) under NBI-ME system ([Fig. 1D,E](#f1){ref-type="fig"}), or a well-demarcated Lugol-unstained area ([Fig. 1F](#f1){ref-type="fig"}) with a diameter ≧5 mm or any Lugol-voiding lesions accompanied with pink color change 3 minutes after spraying Lugol's solution which is often associated with high-grade neoplasia[@b4][@b19][@b20]. Finally, the stomach, the first and second portions of the duodenum, were examined under WLI endoscopy. Endoscopic biopsy was done for all suspicious lesions fulfilling the defined criteria.

Histopathology and tumor board meeting for the treatment strategy
-----------------------------------------------------------------

The biopsied tissues were examined by experienced pathologists and classified by the revised Vienna classification of epithelial neoplasia[@b21]. Negative for neoplasia/dysplasia was classified as category 1, chronic inflammation and squamous hyperplasia belonging to the diagnosis of indefinite for neoplasia were classified as category 2, non-invasive low-grade intraepithelial neoplasia (LGIN) was classified as category 3, high-grade intraepithelial neoplasia (HGIN) and carcinoma-*in-situ* were classified as category 4, and intramucosal or submucosa invasive carcinomas were category 5[@b21]. Patients with synchronous ESCNs with categories 1 and 2 received IEE survey with interval of 6-month, and those with categories 3\~5 were considered to be managed[@b22]. The 7^th^ edition of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control tumor-node-metastasis system was used for tumor staging[@b23], and the treatment planning was made by tumor board review which was composed of expert opinions from gastroenterologists, radio-oncologists, surgical and medical oncologists. After a complete review of the medical condition of each patient and the information from loco-regional status, endoscopic and radiological examinations of primary tumors and SPTs, the final treatment options were made.

Outcome Measurements and Statistical Analysis
---------------------------------------------

We followed the survival condition of recruited patients. The over follow-up time was measured from initial diagnosis of primary cancer and till final death. If patients were lost during follow-up, they were classified as censors. The progression of dysplastic esophageal lesion was also followed by 6-month interval of surveillance EGD and recorded. Continuous data were expressed as mean (±standard deviation) or median (±interquartile range), category data were expressed as number (percentage). The overall survival of patients with/without SPTs of upper gastrointestinal (UGI) tract was plotted in Kaplan-Meier survival plots and Log-rank tests were used to compare overall survival (OS). Univariate and multivariate Cox-regression were used to test significant predictors for OS. All statistical analyses were accomplished using Stata software, version 12.0 (StataCorp LP, College Station, TX).

Results
=======

Demographic data of study population
------------------------------------

Totally two hundred and twenty-five HNSCC patients were diagnosed during the study period. One hundred and forty-five patients (66%) fulfilled the inclusion criteria and recruited in our study ([Table 1](#t1){ref-type="table"}). Their age was 56.1 (±9.8) years old and the female-to-male ratio was 6:94. The location of index primary tumors was oral cancer (63/43, no./%), oropharyngeal cancer (31/21), hypopharyngeal cancer (30/21), laryngeal cancer (16/11), and other HNSCCs (5/4). Among 80 head and neck cancer patients (demographic data shown in [Supplementary Table 1](#S1){ref-type="supplementary-material"}) excluded from enrollment, five patients have allergic history to iodine, eight were salivary gland tumors, sixteen patients had trismus due to betel quid chewing, eighteen presenting tumor bleeding and impending airway compromised, and thirty-three refused IEE screening after informing the possible adverse effects from Lugol's solution spraying. Study population was separated into two groups: synchronous ESCNs with revised Vienna classification of epithelial neoplasia categories 1\~3 (group I), and categories 4\~5 and other UGI tract malignancies (group II), with total number of 123 (84.8%) and 22 (15.2%) patients, respectively. The gender, age, clinical staging of index primary tumors, and status of habitual use of alcohol, cigarette, and betel quid were not significantly different between two groups. Higher proportion of hypopharyngeal cancers were noted in group 2 patients than those in group 1 (54% vs. 15%, p = 0.003). Higher proportion of alcohol drinkers was found in group 2 patients (86% vs. 68%, p = 0.085), but without statistically significance.

Histopathology, stages and treatments of synchronous UGI neoplasia
------------------------------------------------------------------

A total of 67 biopsies of suspicious ESCNs and UGI tract neoplasia were carried out in 145 HNSCC patients. Regarding the histopathology, two, twenty-six (ten inflammation, sixteen squamonus hyperplasia), thirteen, eight and twelve biopsied esophageal samples were belonging to the revised Vienna classification category 1, 2, 3, 4, and 5, respectively. Two inadequate samples for histopathological diagnosis (probably esophagitis by IEE findings), two gastric adenocarcinomas, one esophageal subepithelial tumors and one Barrett's esophagus were noted. [Table 2](#t2){ref-type="table"} showed the characteristics of the HNSCC patients with synchronous SPTs of UGI tract, including 20 ESCNs (Vienna classification 4&5) and 2 gastric adenocarcinomas. Among those with synchronous ESCNs, 8 were HGIN (clinical stage 0), 6 were stage I (3 stage IA, 3 stage IB), 2 were stage II, 1 were stage IIIA and 3 were stage IV. Two were with synchronous gastric adenocarcinomas stage II and IV.

Treatments of SPTs were also shown in [Table 2](#t2){ref-type="table"}. Among HNSCC patients with synchronous esophageal HGIN, three patients (case 1, 4, 7) underwent ESD for esophageal lesions, four (case 2, 8, 9, 10) received endoscopic surveillance only because of short expected lifespan of primary tumors at advanced stages, poor nutrition and performance status, one (case 3) received concurrent chemoradiotherapy (CCRT) for both primary hypopharyngeal cancer and superficial ESCN. Among those with synchronous esophageal invasive carcinoma, one (case 19) underwent esophagectomy, two (case 5, 12) with esophagectomy and CCRT, six (case 6, 11, 13, 16, 17, 18) with CCRT only, and three patients (case 14, 15, 20) with initial predicted invasiveness of lamina propria by IEE underwent ESD with pathological reporting microinvasion of superficial submucosa layer. One patient (case 21) with gastric cancer underwent gastrectomy with chemotherapy and another one (case 22) received gastrectomy who developed metachronous ESCC at stage IIA four years later (loss follow-up for 2 years). Those with synchronous esophageal HGIN (case 2, 3, 8\~10) without treatment remained histologically unchanged by surveillance IEE during study period.

Overall Survival for HNSCC patients according to the existence of synchronous UGI neoplasia
-------------------------------------------------------------------------------------------

At a follow-up of 2.72 (±1.73) years, the median OS was 3.06 years (interquartile range ± 3.21 years). The overall 3-year survival rate was 0.71 (±0.04, 95% CI: 0.62\~0.78). The OS rates of HNSCC patients according the existence of synchronous ESCNs and other UGI tract malignancies were shown in [Fig. 2](#f2){ref-type="fig"}. When comparing the OS among the HNSCC patients who developed a SPT to those who did not, there was a statistically significant difference ([Fig. 2A](#f2){ref-type="fig"}, p  = 0.003 Log-Rank test). HNSCC patients with advanced stages (III&IV) synchronous ESCN had worst survival rates ([Fig. 2B](#f2){ref-type="fig"}, log-rank test p \< 0.001). Using early HNSCC patients without synchronous ESCN as reference by cox regression analysis of survival, hazard ratios for advanced HNSCC patients without synchronous ESCN, those with synchronous early ESCN, and those with synchronous advanced ESCN were 2.02 (95% CI 0.9\~4.55, p = 0.09), 3.70 (1.45\~9.48, p = 0.01), and 39.36 (9.2\~168.1, p \< 0.01), respectively. Among advanced HNSCC patients, those without early ESCN, including HGIN and stage I&II esophageal cancers, had better survivals than those with synchronous lesions, but without statistical significance ([Fig. 2C](#f2){ref-type="fig"}, p = 0.47). Cox regression analysis revealed that male gender, older age, advanced stages of primary tumors were associated with poorer outcomes, but without statistically significance ([Table 3](#t3){ref-type="table"}). Among those with synchronous ESCNs, hypopharyngeal cancers were associated with poorer prognosis when compared with oral cancers at univariate analysis (HR 2.36, 95% CI 1.08\~5.15; p = 0.03). HNSCC patients with existence of esophageal/UGI tract neoplasia had poorer prognosis than those without, both at univariate (HR 2.92/2.85, 95% CI 1.37\~6.22/1.38\~5.87, both p \< 0.01) and multivariate analyses (HR 2.75/2.79, 95% CI 1.11\~6.82/1.15\~6.80, p = 0.03/0.02).

Discussion
==========

The development of SPTs of UGI tract, especially esophagus, in HNSCC patients was not uncommon and usually associated with poor prognosis[@b2][@b3][@b24]. The incidence of synchronous SPTs outside head and neck region in HNSCC patients varies from 7\~36%, and about 3.2\~28% of HNSCC patients had synchronous esophageal neoplasia through IEE screening[@b4][@b5][@b6][@b7][@b8][@b9][@b15][@b16]. Carcinogenesis at multiple loci of squamous epithelium is common in HNSCC patients. Without routine endoscopy screening, the occurrence of synchronous or metachronous SPTs has been reported to be associated with poor prognosis. In a Turkish study of 1,112 HNSCC patients, Erkal *et al.* have demonstrated 7% and 9% patients presented with synchronous and metachronous neoplasia of head and neck mucosal sites, respectively[@b5]. The OS rate was 31% (*vs.* 45% for all enrolled patients) and the disease-specific survival rate was 50% (*vs.* 67%) at 5 years after diagnosis of metachronous HNSCC[@b5]. Notably, seven patients (1%) developed metachronous ESCN at 1 to 11.1 years (median, 2.8 years), and 83 patients (7%) developed metachronous lung cancers at 0.6 to 17.6 years (median, 3.5 years)[@b5]. Another long-term prospective study with a minimum follow-up of 10 years of 2,063 HNSCC patients showed an incidence of 17% for metachronous SPTs with median survival of 12 months only[@b25]. Moreover, the longer survival of HNSCC patients comes with higher incidence of SPTs. A Korean study of 937 HNSCC patients revealed the cumulative SPT incidence of 7.2% at 0 to 6 months (synchronous), 17.9% at 5 years, and 23.1% at 10 years after index primary tumor diagnosis[@b9]. These cohort studies without routine screening for SPTs highlighted the importance and impacts of SPTs in HNSCC patients.

HNSCC patients are at high risk for synchronous SPTs, especially neoplasia of UGI tract which is exposed to same environmental carcinogens as primary sites, illustrating the concept of "field cancerization"[@b1][@b2][@b3]. With the development of SPT of UGI tract in HNSCC patients, the prognosis is usually very poor despite advances in intensive multidisciplinary treatment strategy for HNSCC[@b2][@b3][@b5][@b9][@b25][@b26]. In the present study, we found that the incidence (15.2%) of SPT located at UGI tract using IEE screening in HNSCC patients was not low. HNSCC patients with synchronous esophageal/UGI tract neoplasia had poorer survival (HR 2.75/2.79, 95% CI 1.11\~6.82/1.15\~6.80, p = 0.03/0.02 in multivariate analyses). We also demonstrated that newly-diagnosed HNSCC patients with synchronous esophageal neoplasia at late stage (III&IV) had the worst outcome ([Fig. 2B](#f2){ref-type="fig"}). The result shed lights on the importance of routine IEE screening of UGI tract neoplasia in newly-diagnosed HNSCC patients for risk stratification and prognosis prediction.

Recent advances in IEE imaging by means of dye-based or optical-based techniques have enabled precancerous or early cancerous lesions visible more easily than traditional WLI endoscopic examination[@b27]. Using IEE examination, especially chromoendoscopy with Lugol's solution and NBI system with high-resolution ME, dysplastic or cancerous lesions, and tumor invasion could be well delineated and predicted[@b18]. Intentional IEE screening of esophagus in HNSCC patients identified higher proportion of SPTs (27.2% *vs.* 5.3%)[@b16]. Through IEE screening esophagus in HNSCC patients, a high incidence up to about 28% synchronous ESCN could be identified before obstructive symptoms develop[@b7][@b8][@b15][@b19]. Our previous experience has found 23.3% synchronous ESCN, including LGIN to invasive carcinoma in HNSCC patients and 15.5% treatment strategy of them had been modified after IEE screening for esophagus[@b8]. In this study, 15.2% HNSCC patients had advanced synchronous ESCN, including HGIN to invasive carcinoma, by IEE screening. Notably, the majority ([Tables 2](#t2){ref-type="table"}, 63.6% clinical stage 0 and I) of synchronous ESCN were at early stage without obstructive symptoms which made curative treatment of synchronous esophageal SPTs possible. However, poor nutrition and performance status of HNSCC with advanced ESCN hamper the concurrent treatment, which may lead to worst prognosis among these patients ([Fig. 2B](#f2){ref-type="fig"}).

Due to the diversity of SPNs, the best management policy is still inconclusive. In this study, five patients presented early synchronous ESCN at stage 0 with stage III&IV primary index tumors received watch and wait or CCRT for SPTs, and none of them died of SPTs ([Table 2](#t2){ref-type="table"}). On the other hand, two esophageal SPTs at stage IB with primary index tumor at stage II and IV died of SPTs despite concurrent treatment of primary and secondary tumors. Among advanced HNSCC patients, although there was a trend for better survivals for those without early ESCN, the difference in survival was not statistically significant ([Fig. 2C](#f2){ref-type="fig"}). Therefore, whether treatment of early SPTs in HNSCC patients with advanced stages improves their outcomes remains controversial and randomized studies with large sample size are needed to elucidate this issue.

Given that the occurrence of SPTs is associated with poor prognosis in HNSCC patients, identification of SPTs is considered to be beneficial for survival and cost-effective. A simulated Markov model-based analyses in an area with high risk for ESCN, China, has demonstrated that screening six times between 40--70 years at a 5-year interval yielded the highest net present value and benefit-cost ratio[@b28]. Thus, screening ESCN in high risk population including HNSCC patients should be cost-effective. A longitudinal cohort study compared the survival rates between HNSCC patients with and without routine IEE screening for ESCN[@b16]. The survival was better for those who received screening than those who did not (HR 0.57, 95% CI 0.41--0.79) and the Cox regression model quantified a survival benefit of 29% by IEE screening[@b16]. However, the real incidence of the occurrence of synchronous ESCN was unrevealed in HNSCC patient without IEE screening and lead-time bias existed in the retrospective study[@b16]. In our prospective study, every enrolled HNSCC patients underwent IEE screening for UGI tract neoplasia. The results have shown that the survival estimates were not influenced by the synchronous ESCN despite identification and treatment of SPTs, and as expected, the worst outcome was noted in HNSCC patients with advanced synchronous ESCN ([Fig. 2B](#f2){ref-type="fig"}).

There were some limitations in our study. First, the sample size was small and follow-up period was short in this prospective cohort study conducted in one tertiary center. Large scale clinical trials in multicenter units with long time observation are needed to verify our results. Second, the treatment of identified SPTs was not standardized or randomized. However, it is difficult to conduct a randomized clinical trial to evaluate the impacts of treatment for early SPTs in those at advanced stage of index tumor based on individualized medicine approaching. The treatment strategy in this study was decided by tumor board conference and according to the status of nutrition, performance, location and staging of index and second primary malignancies. Additionally, underlying comorbidities were not included for survival analysis.

In conclusion, IEE screening could identify SPTs of UGI tract before symptoms develop and curative treatment of SPTs becomes possible by early endoscopic screening. The presence of SPTs was associated with poor prognosis, especially in those with advanced stage. By IEE screening, early prognostic stratification of HNSCC patients could be achieved. In this prospective design study which was different from previous similar study using historical controls[@b16], survival benefits from IEE screening were not seen. However, further clinical trials are warranted to evaluate the benefits of treatment for early SPTs of UGI tract in advanced HNSCC patients.
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![(**A**,**B)** A right-sided hypopharyngeal cancer. (**C**) An uneven hyperemic mucosa surface under white-light endoscopy. (**D**,**E**) Brownish discoloration of mucosa with abnormal microvasculatures under narrow-band imaging with magnifying endoscopy. (**F**) A well-demarcated Lugol-unstained area. Pathology from endoscopic submucosal dissection reporting squamous cell carcinoma invading the lamina propria.](srep29573-f1){#f1}

![(**A**) Survival of head and neck squamous cell carcinoma (HNSCC) patients with synchronous upper gastrointestinal (UGI) tract neoplasia versus those without lesions. (**B**) Survival estimates according to staging of primary tumors and existence of synchronous esophageal neoplasia. (**C**) Survival estimates of advanced (stage III&IV) HNSCC patients with early esophageal neoplasia (stage 0\~II) and those without lesions.](srep29573-f2){#f2}

###### Demographic data of recruited patients.

  Characteristics             N = 145     (%)    Group I (n = 123)   Group II (n = 22)    p-value
  ------------------------- ------------ ------ ------------------- ------------------- -----------
  Sex (F/M)                    8/137      6/94         6/117               2/20          0.425^β^
  Age (years)                56.1 ± 9.8            55.57 ± 0.87        59.13 ± 2.15      0.117^@^
  Primary site                                                                           0.003^\#^
   Oral cancer                   63        43           58                   5                
   OP cancer                     31        21           28                   3                
   Hypopharyngeal cancer         30        21           18                  12                
   Laryngeal cancer              16        11           14                   2                
   Other cancers                 5         4             5                   0                
  Clinical-stage                                                                         0.850^\#^
  1                              28        20           25                   3                
  2                              21        15           18                   3                
  3                              20        14           16                   4                
  4                              71        51           60                  11                
  Alcohol drinking              103        71           84                  19           0.085^\#^
  Betel quid chewing             91        63           80                  11           0.179^\#^
  Cigarette Smoking             121        83           101                 20           0.307^\#^
  Biopsy results (n = 67)                                                                     
  Vienna classification                                                                       
   1. Negative                   2         3                                                  
   2. Inflammation               26        39                                                 
   3. LGIN                       13        19                                                 
   4. HGIN                       8         15                                                 
   5. Invasive Carcinoma         12        15                                                 
   6. Other\*                    6         9                                                  

Group I: synchronous ESCNs with revised Vienna classification of epithelial neoplasia categories 1\~3

Group II: synchronous ESCNs categories 4\~5 and other UGI tract malignancies (group II).

LGIN: low-grade intraepithelial neoplasia; HGIN: high-grade intraepithelial neoplasia.

\*Non-made: 2; Gastric cancer: 2; Esophageal submucosal tumor:1; Barrett's esophagus: 1.

^β^Fisher's exact test; ^@^t-test; ^\#^Chi-square test.

###### Patients with the diagnosis of esophageal cancer and high grade dysplasia 22/145 (15.2%).

  Case      Primary tumor   cStage     SPT     cStage   Tx of SPT   Outcome
  -------- --------------- -------- --------- -------- ----------- ---------
  1            Larynx         I      EsoHGIN     0         ESD        LF
  2             Hypo          IV     EsoHGIN     0         F/u        DH
  3             Hypo          IV     EsoHGIN     0        CCRT        DH
  4          Oropharynx       IV     EsoHGIN     0         ESD        DH
  5             Hypo         III      ESCC      IIIA     OP+CCRT      DH
  6             Oral          IV      ESCC       IB       CCRT        DE
  7             Hypo          IV     EsoHGIN     0         ESD        DH
  8             Hypo         III     EsoHGIN     0         F/u        NA
  9             Oral          IV     EsoHGIN     0         F/u        DH
  10            Oral          IV     EsoHGIN     0         F/u        NA
  11            Hypo          IV      ESCC       II       CCRT        NA
  12         Oropharynx       II      ESCC       IB      OP+CCRT      DE
  13            Hypo          IV      ESCC       IV       CCRT        DH
  14            Oral          II      ESCC       IA        ESD        DH
  15            Hypo         III      ESCC       IA        ESD        LF
  16         Oropharynx       IV      ESCC       IV       CCRT        NA
  17            Hypo         III      ESCC       IV       CCRT        DE
  18            Hypo          IV      ESCC       II       CCRT        LD
  19           Larynx         I       ESCC       IB        OP         DH
  20            Hypo          IV      ESCC       IA        ESD        LD
  21            Oral          IV       GA        IV       OP+CT       DH
  22^\*^        Hypo          IV       GA        II        OP         NA

LF: Live without disease; LD: Live with disease; DH: Death due to HNSCC; DE: Death due to ESCN; F/u: follow-up; NA: Loss of F/u.

^\*^Metachronous ESCC stage IIA 4 years later.

###### Survival analysis with Cox Regression.

                     Univariate Hazard ratio          95% CI              p-value      Multi-variate Hazard ratio          95% CI            p-value
  ----------------- ------------------------- ----------------------- --------------- ---------------------------- ----------------------- -----------
  Sex (M/F)                 1.44/1.46          0.35\~5.96/0.35\~6.03     0.62/0.60             1.45/1.45            0.34\~6.18/0.34\~6.16   0.62/0.62
  Age                       1.00/1.01          0.97\~1.04/0.98\~1.05     0.79/0.46             0.99/1.01            0.96\~1.03/0.97\~1.04   0.74/0.78
  Stage                                                                                                                                    
  III&IV vs. I&II           1.94/1.97          0.98\~3.87/0.99\~3.90     0.06/0.05             1.81/1.87            0.85\~3.84/0.88\~3.95   0.12/0.10
  Primary site                                                                                                                             
   Oral                       1.00                                                                1.00                                           
   OP                       1.27/1.19          0.57\~2.82/0.54/2.63      0.56/0.66             1.12/1.01            0.49\~2.55/0.45\~2.27   0.79/0.99
   Hypo                     2.36/2.06          1.08\~5.15/0.95\~4.45     0.03/0.07             1.27/1.01            0.49\~3.29/0.39\~2.64   0.62/0.98
   Larynx                   1.21/1.14          0.44\~3.35/0.41\~3.12     0.71/0.81             1.10/0.99            0.39\~3.12/0.35\~2.78   0.86/0.98
   Other                    0.69/0.65          0.09\~5.26/0.09\~4.94     0.72/0.68             0.65/0.65            0.08\~4.99/0.09\~4.99   0.68/0.68
  PES                                                                                                                                      
   With SPT                 2.92/2.85          1.37\~6.22/1.38\~5.87   \<0.01/\<0.01           2.75/2.79            1.11\~6.82/1.15\~6.80   0.03/0.02

Reported as esophageal neoplasia only/upper gastrointestinal tract neoplasia (including two gastric cancers).
